Weili Sun, M.D., Ph.D.

  • Associate Clinical Professor, Department of Pediatrics
  • Director, Pediatric Leukemia Program
  • Pediatric Hematologist/Oncologist

Weili Sun, M.D., Ph.D.

Clinical Specialties
  • Pediatric Hematology-Oncology
Areas of Expertise
  • Pediatric leukemia and lymphoma
Research Focus
  • Early phase clinical trials in pediatric leukemia and lymphoma
Other Languages Spoken
  • Mandarin
  • Cantonese

Weili Sun, M.D., Ph.D., is an associate clinical professor in the Department of Pediatrics. She also serves as director of the Pediatric Leukemia Program. Double board-certified in pediatrics and pediatric hematology/oncology, Dr. Sun’s clinical and research interests include developing novel therapeutic agents to treat children, adolescents and young adults with newly diagnosed and relapsed leukemia and lymphoma.  

Dr. Sun joined City of Hope from Children’s Hospital Los Angeles (CHLA) and Keck School of Medicine of USC. While at CHLA, she was a member of the scientific review committee of the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium, a multi-institutional scientific consortium focusing on early phase clinical trials in pediatric leukemia and lymphoma. 

She was the study chair of several multi-institution TACL clinical studies, including a phase 1 study using azacitidine in combination with chemotherapy to treat childhood relapsed acute leukemia. In addition, she is the study committee member of the Children’s Oncology Group’s phase 3 study to treat children with newly diagnosed acute promyelocytic leukemia. Dr. Sun has received multiple external peer-reviewed grants for her clinical and translational research work. She has published her work in many peer-reviewed journal and has been invited to speak at national and international meetings.

  • 2016-present, Associate Clinical Professor, Department of Pediatrics and Director, Pediatric Leukemia Program, City of Hope, Duarte, CA
  • 2011-2016, Assistant professor, Keck School of Medicine of USC, Children’s Hospital Los Angeles, Pediatrics, Los Angeles, CA


1500 East Duarte Road, Duarte, CA, 91010

Get Directions

Phone :  626-256-4673


  • 2004, University of Tennessee, Health Science Center, St. Jude Children’s Hospital, Memphis, TN, Ph.D.
  • 1995, Sun Yat-Sen University of Medical Sciences, Guangzhou, China, M.D.


  • 2008-2011, Memorial Sloan-Kettering Cancer Center, Pediatric Hematology/Oncology, New York, NY


  • 2007-2008, Montefiore Medical Center, Pediatrics, Bronx, NY
  • 2006-2007, Sinai Hospital of Baltimore, Pediatrics, Baltimore, MD


  • 2005-2006, Sinai Hospital of Baltimore, Pediatrics, Baltimore, MD
  • 2013, Pediatric Hematology Oncology
  • 2008, American Board of Pediatrics
  • Li L, Qi X, Sun W, Abdel-Azim H, Lou S, Zhu H, Prasadarao NV, Zhou A, Shimada H, Shudo K, Kim Y-M,  Khazal S, He Q, Warburton D, Wu L. (2016) Am80-GCSF synergizes myeloid expansion and differentiation to generate functional neutrophils that reduce neutropenia-associated infection and mortality (accepted to EMBO Molecular Medicine)
  • Sun W, Orgel E, Malvar J, Sposto R, Wilkes J, Gardner R, Pineros V, Smith A, Hur M, Hoffman J, Rheingold SR, Burke MJ, Wayne AS. (2016) Treatment related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia (Pediatric Blood and Cancer,  DOI: 10.1002/pbc.26129. [Epub ahead of print])
  • Yeo KK, Gaynon P, Fu C, Wayne A, Sun W. (2016) Bortezomib, dexamethasone, mitoxantrone and vinorelbine (BDMV): an active re-induction regimen for children with relapsed ALL and Asparaginase intolerance (Journal of Pediatric Hematology Oncology, 38 (5): 345-9)
  • Gaynon P, Sun W. (2016) Oligoclonality and a new agent evaluation in acute lymphoblastic leukemia (British Journal of Haematology, 173 (6): 950-957)
  • Sun W, Gaynon P, Sposto R, Wayne A. (2015) Improving access to nove1 agents for childhood leukemia (Cancer, 121 (12): 1927-36)
  • Liu Y, Tang J, Wakamatsu P, Xue H, Chen J, Gaynon PS, Shen S, Sun W. (2014) High-resolution melting curve analysis, a rapid and affordable methods for mutation analysis in childhood acute myeloid leukemia (Frontiers in Pediatrics, 2:96, DOI:10.3389/fped.214.00096)
  • Sun W, Modak S. (2012) Emergenging treatment options for the treatment of neuroblastoma: potential role of periforsine (Onco Targets and Therapy, 5:21-29)
  • Lorsbach RB, Moore J, Ang S, Sun W, Lenny N, Downing JR. (2004) Role of RUNX1 in adult hematopoiesis: analysis of RUNX1-GFP knock-in mice reveals differential lineage expression (Blood. 2004, Apr 1; 103(7):2522-9)
  • Sun W, Downing JR. (2004) Haploinsufficiency of AML1 results in a decrease in number of LTR-HSC, while simultaneously inducing an increase in more mature progenitors (Blood, 2004, Dec 1;104(12):3565-72)
  • 2014-present, Chinese American Hematologist and Oncologist Network
  • 2013-present, European Hematology Association
  • 2008-present, Children’s Oncology Group
  • 2011-present, American Society of Clinical Oncology
  • 2008-present, American Society of Pediatric Hematology/Oncology
  • 2003-present, American Society of Hematology
Back To Top